

Uriviga S

Tablets

**Tamsulosin Hydrochloride I.P. 400 mcg &
Solifenacin Succinate I.P. 6 mg**



Relieves lower urinary tract symptoms associated with **BPH**.



Reduces **urinary urgency, frequency, and nocturia**.



Improves **bladder storage** symptoms with dual-action therapy.



Enhances **urinary flow** and bladder control.



Well tolerated with a **proven safety** profile.

Indications

Benign Prostatic
Hyperplasia (BPH)

Lower Urinary
Tract Symptoms (LUTS)

Overactive
Bladder Symptoms

Urinary Urgency
& Frequency

Nocturia
Management

References:

- European Association of Urology (EAU). Guidelines on the Management of Non-neurogenic Male LUTS. EAU Guidelines Office; Latest Edition.
- American Urological Association (AUA). Guideline: Management of Benign Prostatic Hyperplasia (BPH). AUA; Latest Edition.
- Chapple CR, et al. Combination therapy with tamsulosin and solifenacin in men with LUTS. European Urology. 2013;63(2):316–323.
- Oelke M, et al. Efficacy and safety of combination therapy in LUTS/BPH patients: A systematic review. World J Urol. 2014;32(1):101–112.
- Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th Edition.
- British Pharmacopoeia 2023 – Volume II.